patient
What is PNH? Recorded Session from the 2025 San Francisco Bay Area Patient and Family Conference
Transplant and GVHD: Aplastic Anemia and PNH - 2025 San Francisco Bay Area Conference
23-Year Aplastic Anemia Survivor Speaks - 2025 San Francisco Bay Area Patient/Family Conference
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
Abstract
Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Key Points
Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD.
Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management
Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched related blood stem cell donor with reduced-intensity or myeloablative conditioning, according to results from the phase 3 BM12 CAST trial (ACTRN12618000505202) presented during the European Hematology Association 2025 Congress.1
Treatment patterns and blood count control in 10,112 patients with polycythemia vera
ABSTRACT
Background
Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contributes to morbidity and mortality.
Research design and methods
This retrospective study describes treatment patterns and blood count control in patients with PV managed at community oncology practices (January 2014–February 2023; Integra Precision Q database).
BEXMAB Study: Dr. Amer Zeidan Remarks on the Results’ Meaning for MDS Care
Amer Zeidan, MBBS, MHS, is professor of internal medicine at Yale School of Medicine in New Haven, Connecticut. He is also the chief of the Division of Hematologic Malignancies at Yale Cancer Center, New Haven.
Dr. Zeidan spoke with Blood Cancers Today about the phase 1/2 BEXMAB study, which was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, recently held in Chicago, Illinois, and will be presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.